Two Onc Docs

This week’s episode will be focusing on treatment options for localized breast cancer. We will go all the important details on radiation, as well as therapies based on what the ER/PR/her2 receptor status is.

We are providing 2026 update for our breast cancer episodes, today we cover an introduction on breast cancer screening, prevention.

This week’s episode we are very excited to welcome back our special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We further cover the topic of ctDNA, uses, limitations, and future directions.

This week’s episode we are very excited to welcome a special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We cover the topic of liquid biopsies, ctDNA, NGS panels definitions & current uses.

This week's episode focuses on metastatic non-small cell lung cancer - the quickly growing and changing systemic therapy landscape, including traditional chemotherapy, immunotherapy, and targeted agents. Since our last recording the number of FDA-approved targeted drugs has significantly expanded.

This week's episode focuses on early-stage and locally advanced non-small cell lung cancer - staging, pathology, local and systemic therapy. Before we start, the usual caveat: the treatment landscape of NSCLC is changing FAST, which is exciting, but know that the boards run a few years behind. The big shifts since our last episode are the move to 9th-edition TNM staging and the arrival of four different perioperative chemo+immunotherapy regimens. Shout out to Dr. Bharathi Muthusamy for review...

Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS). This will include the high yield facts on risk factors, diagnostic work-up, staging and treatment of MDS, we were overdue do this this topic, last done in 2022.

This week’s episode will be focusing on syndromes of iron overload. We will go over all important details on hemochromatosis and other related diseases. We last covered this topic in 2023.

This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect.

This week’s episode will be focusing on how to transition well into heme/onc fellowship including differences from residency, tips for surviving, wellness, resources & more.

This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL

This week’s episode we are back with our very special guest, friend and colleague Dr Laura Vater joining us to talk about wellness in oncology, and burnout prevention tips.

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending. Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patients and clinicians, and strives to keep healthcare human.

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial. The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions.

This week’s episode will be focusing on Von Willebrand disease (VWD), a highly testable bleeding disorder. We will go over all the important details on the diagnosis, types of VWD as well as treatment.

Today’s episode is focusing on the highest yield facts about Aplastic Anemia. This will include the mechanism of AA, diagnostic work-up, treatment of AA, and the evolution of clones including PNH.

Today’s episode is focusing on what you need to know regarding metastatic bladder cancer, with 2026 updates. This will include the need to know treatment options and toxicities for metastatic urothelial carcinoma, and also discuss the management of upper tract + variant non-urothelial histology.

Today’s episode is focusing on what you need to know regarding localized bladder cancer, with 2026 updates. This will include the need to know pathology, presentation, diagnostic work-up, staging, and treatment options.

This week’s episode will be focusing on how we met, the future of the podcast, and why we picked heme/onc. This is a very different style of episode and a special once because this month is our 4 year anniversary of Two Onc Docs! And we will back to our regular programming next week with overdue updates on Bladder Cancer.

We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 3, we discuss supportive care in pancreatic cancer, and exciting trials in this space.

We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 2, we will focus on metastatic pancreatic cancer, 1L treatments, maintenance therapy, targeted therapy + more.

This week’s episode will be discussing Pancreatic Cancer with a very special guest Dr. Michael Pishvaian. Dr. Pishvaian is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 1, we will focus on risk factors, diagnosis and treatment of localized pancreatic cancer.

This week’s episode will be focusing on a recap of some of the important data ASCO GU just held in San Francisco end of February. We will go over some topics in prostate, RCC, bladder cancer, and other GU tumors.

This week’s episode will be focusing on Neuroendocrine Tumors (NET). We will go over all the important details regarding the heterogeneous group of NETs, diagnosis, work-up, treatment, and focus mostly on gastro-entero-pancreatic NETs.

This week’s episode we are back with our special guest & thrombosis expert Dr. Marc Carrier. In part 2, we discuss additional special considerations like IVC filter indications, and management of VTEs in the setting of thrombocytopenia. We also discuss VTE prevention in patients with cancer, the Khorana score, exciting research to come in this space, and career advice.

This week’s episode will be focusing on a very important topic, with our special guest Dr. Marc Carrier. Dr. Carrier is a Professor in the Faculty of Medicine, and holds a Tier 1 Clinical Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. We discuss the work-up and treatment of VTEs and cancer, including types of anti-coagulation, duration, and special considerations.

This week’s episode we discuss what to look forward to at ASCO GU this week. Held in SF Feb 26-28 in San Francisco. We will go over the program in prostate cancer, kidney cancer, bladder cancer, as well as testicular cancer.

This week’s episode, we are back with our special guest Dr. Ria Kraft, a radiation oncologist and host of Rad Onc Talks. In part 2, we go over important details on duration + fractionation schemes, indications for palliative RT, other indications for RT in metastatic disease, and more.

This week’s episode will be focusing on basics of radiation oncology. We are so excited to welcome a special guest Dr. Ria Kraft, who has a YouTube channel called Rad Onc Talks for radiation oncology education. In part 1, we go over important details on types of radiation, how it works, the patient experience, common side effects and more.

This week’s episode we are so excited to welcome Dr. Chadi Nabhan, who is a hematologist and medical oncologist, author, and host of Healthcare Unfiltered. We discuss why oncology, our career paths, different career paths in hematology and oncology, contract & negotiation considerations, as well as tips to search for a job.

This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition. In part 2, we will go over dietary strategies focusing on cancer prevention, and myths around what causes cancer.

This week’s episode is a new topic! We will be focusing on basics of nutrition in oncology. We are so excited to welcome a very special guest Dr. Krystle Zuniga, who is a board-certified specialist in oncology nutrition. In part 1, we will go over information + myths in oncology nutrition including cancer feeds sugar, fiber, estrogen, supplements, fasting, and more.

Happy New Year! This week’s episode will be focusing on 2026 update for Follicular Lymphoma. We will go over the important details on the diagnostic criteria, indications for treatment and types + toxicities of treatment.

This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).

This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST with a 2025 update. We will go over important details on the diagnosis, mutations, and treatment of local and metastatic GISTs.

This week’s episode is also due for an update since it aired in 2022. Will be focusing on Hodgkin Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.

Today’s episode is focusing on what you need to know regarding Anal cancer. This was one of our first episodes back in 2022 so it is time for an updated episode! This will include the important details on risk factors, diagnostic work-up, staging and treatment of both localized and metastatic anal cancer.

This week’s episode will be on many exciting updates were announced at ESMO this October in Berlin from Oct 17-21, 2025, especially in bladder cancer, we continue to make such progress! We discuss key trials in NMIBC (POTOMAC), MIBC (KN-905, IMvigor-011), and metastatic urothelial carcinoma (FORAGER-1, DV + Toripalimab).

This week’s episode will be focusing on details of the hematology & oncology board exams, how we prepared the days leading up to our exam, and we cover some highly tested topics in both hematology & oncology. We wish the best of luck to everyone taking their boards this year!

This week’s episode will be focusing on Porphyrias…which is very timely since this week is HALLOWEEN and porphyrias are the diseases many people believe started the vampire legend!

This week’s episode is part 3 of our breast cancer series, with a 2025 update focusing on metastatic breast cancer systemic therapies, toxicities, and supportive care considerations.

This week’s episode will be focusing on treatment options for localized breast cancer with 2025 updates. We will go over important details on indications for adjuvant radiation, as well as therapies based on the ER/PR/HER-2 receptor status.

October marks Breast Cancer Awareness Month. We are providing 2025 update for our 3 part breast cancer episodes, in part 1 today we cover an introduction on breast cancer screening, prevention.

This week’s episode will be focusing on Esophageal and Gastrosophageal Junction (GEJ) Cancer. We will go over important details on the risk factors, diagnosis, and treatment for both localized and metastatic esophageal cancer.

This week’s episode will be focusing on Immune Thrombocytopenia Purpura ( ITP). We will go all the important details on causes, mechanism, diagnosis and treatment. The last time we covered this topic was in Sept 2022, and this comes up ALL the time in heme consults, and there will definitely be board review questions. It may also be tested on IM boards.

This week’s episode will be an update on Bone Sarcomas. We will go over the important details on diagnosis, staging, subtypes and treatment of a few bone sarcomas. Just like Soft Tissue Sarcomas, these are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes. They are more common in children, and most of our bone sarcoma recommendations that are testable are based on pediatric data.

This week’s episode will be focusing on soft tissue sarcomas. We last recorded this topic in 2023, and well we have some new FDA approvals and updates since then. We will go over the important details on the diagnosis, subtypes and treatment of a few soft tissue sarcomas. These are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes that range from noncancerous tumors such as desmoid tumors to aggressive cancers and everything in between.

Today’s episode will focus on an update for commonly tested Thrombotic microangiopathies (TMA) such as Thrombotic Thrombocytopenic Purpura (TTP). This will include the high yield facts on mechanism, presentation, diagnostic work-up, and treatment of TTP, and also discuss Hemolytic Uremic Syndrome (HUS), and atypical HUS.

This week’s episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.

We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Today’s episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Today’s episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options.

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome.

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship! We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer. We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.

This week’s episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease.

This week’s episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.

This week’s episode will be focusing on exciting data to come at the ASCO Annual Meeting 2025 starting with the plenary sessions, then a special focus on the GU abstracts, including prostate CA, renal cell carcinoma, bladder CA, and a quick shout-out for some of the medical education sessions.

This week’s episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 2 discusses conditioning regimens, graft-vs-host disease, toxicities, and Dr. Auletta's career path.

This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 1 discusses important basics including what a transplant is, types of transplant & associated risks, types of donors, how to find a donor, and barriers/inequities of finding a donor.

This week’s episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.

This week’s episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.

This week’s episode will be focusing on an update of CLL. We will go over important details on the presentation, diagnosis, prognostic factors, and treatment options for initial and refractory disease, as well as key toxicities.

We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'. This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.

We are so excited to welcome Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at Memorial Sloan Kettering in NYC. This episode will cover localized prostate cancer, risk factors, staging, role of PET PSMA, risk stratification, treatments, as well as introduce biochemical recurrence.

Today’s episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.

Today’s episode is focusing on what you need to know regarding early stage colorectal cancer (CRC) as of 2025. The last time we covered this topic was in 2023 and things continue to change. We will go over all the important details on the diagnosis, presentation, diagnostic work-up, role of ctDNA, staging, treatment, and surveillance of localized CRC.

We are so honored to welcome back Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week’s episode will be focusing on additional pearls for the treatment of Multiple Myeloma including options for refractory disease, as well as advice for trainees.

Today we will be discussing a few of the exciting abstracts presented at ASCO GU (Feb 13-15 2025) for prostate CA (TALAPRO-2), bladder CA (EV-302, CM-274, NIAGARA), and RCC (COSMIC-313, KIM-1).

Today we will be discussing exciting data to come at ASCO GU (Feb 13-15 2025) in terms of research for prostate CA, bladder CA, RCC and other rarer GU tumors.

We are so honored to welcome Dr. S. Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He is also Editor-In-Chief of Blood Cancer Journal and the Chairperson of the Board of the International Myeloma Foundation. This week’s episode will be focusing on Multiple Myeloma symptoms, diagnostic criteria, work-up and initial treatment.

This week’s episode will be focusing on additional details for Extensive Stage Small Cell Lung Cancer (SCLC), options for relapsed/refractory disease & advice for trainees. We are so excited to welcome back Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

This week’s episode will be focusing on Small Cell Lung Cancer (SCLC). We will go all the important details on risk factors, diagnostic work-up, staging and treatment of both locoregional and metastatic SCLC. We are so excited to welcome Dr. Stephen Liu international expert for lung cancer, Director of Thoracic Oncology & Developmental Therapeutics at Georgetown Lombardi Cancer Center and Co-Host of the IASLC Podcast.

This week’s episode will be re-discussing one of the myeloproliferative neoplasms, Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification for thrombus and treatment.

Happy New Year! This week’s episode will go over important details related to immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs), with general management strategies for each of the most common iRAEs.

This week’s episode will be focusing on advanced Thymoma and Thymic Carcinoma, board review pearls, and career advice for trainees & early career oncologists. We are back with Dr. Pat Loehrer, who is a legend when it comes to the treatment of Thymoma.

This week’s episode will be focusing on localized Thymoma and Thymic Carcinoma. We are so honored to have Dr. Pat Loehrer here with us today who is a legend when it comes to the treatment of Thymoma. He is a Distinguished Professor of Medicine Joseph W. and Jackie J. Cusick Professor of Oncology, Director for Center of Global Oncology and Health Equity and prior cancer center director at Indiana University.

This week’s episode will be focusing on Metastatic Non-small Cell Lung Cancer (NSCLC). We are back with Dr. Jennifer Marks, Thoracic Oncologist at the Dana-Farber Cancer Institute. We will go all the important details on the quickly growing and changing systemic therapy options including traditional chemotherapy, immunotherapy and targeted agents

This week’s episode will be focusing on Localized Non-small Cell Lung Cancer (NSCLC). We are very excited to have Dr. Jennifer Marks with us today. Dr. Marks is a thoracic oncologist at the Dana-Farber Cancer Institute, Instructor in Medicine at Harvard Medical School, who also recently took her oncology boards. We will go all the important details on basic of staging, treatment for resectable and unresectable localized NSCLC, and updates in terms of peri-operative and targeted therapies

This week’s episode will be focusing on Hemoglobin (Hb) electrophoresis. We will go important details on what Hb electrophoresis is, the normal breakdown of adult hemoglobin, and specific hemoglobinopathies (thalassemias, sickle cell, Lepore...) you can be tested on during your ITEs and hematology boards.

In honor of National Family Health History Month in November, we have a special guest. We share the story of an incredible colorectal cancer survivor and health advocate, Marisa Peters, who was a Broadway vocalist and a very healthy, active mom to 3 young boys, yet diagnosed with stage 3 rectal cancer at only 39 years old.

This week’s episode is part 3 of 2024 updates focusing on treatment options for metastatic breast cancer. We will cover important details on systemic therapy related to metastatic breast cancer & key toxicities. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.

This week’s episode is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.

We are continuing our 2024 updates, this week’s episode will be an intro to breast cancer. Today’s will include high yield tips on screening, prevention, ductal carcinoma in situ DCIS, lobular carcinoma in situ LCIS, as well as introduce invasive localized disease.

This week’s episode will be discussing our favorite heme/onc board review resources. This is pertinent to new fellows who are starting to think about how to study during fellowship, preparation for ITEs and of course studying for the boards.

We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.

In Part 2 we discuss how to deal with patients of different backgrounds, navigating spiritual & emotional challenges in oncology, tips for physicians who are experiencing moral distress & compassion fatigue, as well as general career advice. We are so honored to have Dr. Janet Abrahm with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.

This week’s episode will be focusing on final board review tips. We will go over our highest yield cheat sheet topics, and how we prepared the days leading up to our exam. We took our boards three years ago now, but the stress leading up to the exam is certainly fresh in our minds.

In Part 1 we discuss how to explain palliative care to patients, pain and anti-emetic management, non-pharmacologic strategies, and current innovations within palliative care. We are so honored to have Dr. Janet Abrahm here with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.

This week’s episode will be repeating our episode on hemophilias with some updates. We will go over all high yield facts regarding both hemophilia A and B for your boards and end with a little bit about acquired hemophilias.

This week’s episode will be discussing updates from ASCO 2024 next with the practice changing NADINA trial presented on the Sunday of ASCO by Dr. Christian Blank during the plenary sessions: A multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. We discuss the staging and prior standard of treatment for locally advanced melanoma, key findings from NADINA, and ...

Today’s episode is a continuation on fast facts for the IM Board review focusing on the oncology questions. Another 6% of the certifying ABIM test is oncology. While we can’t cover ALL of oncology in just 10 minutes, here are 10 high yield concepts/facts/vignettes you should know walking into your IM Boards.

Today’s episode focuses on what you need to know to ace the hematology questions for your 2024 IM boards. 6% of the ABIM exam is hematology which includes erythrocyte, leukocyte and platelet disorders, coagulation disorders, transfusion medicine, and heme malignancies. We discuss some common vignettes & high yield points.